These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24665658)

  • 21. Prasugrel versus clopidogrel.
    von Lewinski F; Riggert J; Paulus W
    N Engl J Med; 2008 Mar; 358(12):1299; author reply 1299-301. PubMed ID: 18357639
    [No Abstract]   [Full Text] [Related]  

  • 22. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
    Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clopidogrel versus prasugrel: times are changing, but not for everyone.
    Dobesh PP
    Pharmacotherapy; 2009 Dec; 29(12):1393-6. PubMed ID: 19947798
    [No Abstract]   [Full Text] [Related]  

  • 24. Future of oral antiplatelet therapy: four challenged hypotheses.
    Serebruany VL; Makarov LM
    Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
    [No Abstract]   [Full Text] [Related]  

  • 25. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 26. Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
    Wallentin L; Himmelmann A; Storey RF; Steg PG; Harrington RA;
    Thromb Haemost; 2014 Jul; 112(1):12-4. PubMed ID: 24816949
    [No Abstract]   [Full Text] [Related]  

  • 27. Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.
    Passacquale G; Ferro A
    BMJ; 2011 Jun; 342():d3488. PubMed ID: 21685436
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].
    Preobrazhenskiĭ DV
    Kardiologiia; 2008; 48(8):72-3. PubMed ID: 18789014
    [No Abstract]   [Full Text] [Related]  

  • 29. TRILOGY ACS: prasugrel of benefit only after angiography?
    Swaminathan RV; Feldman DN
    Lancet; 2013 Aug; 382(9892):580-2. PubMed ID: 23953376
    [No Abstract]   [Full Text] [Related]  

  • 30. [The TRITON-TIMI 38 trial].
    De Servi S; Lettino M
    G Ital Cardiol (Rome); 2008 Mar; 9(3):149-54. PubMed ID: 18422094
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Enar R
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):166-71. PubMed ID: 23666308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Antiplatelet Agents in Acute Coronary Syndrome.
    Sachdeva A
    J Assoc Physicians India; 2015 Jan; 63(1):75-6. PubMed ID: 26591137
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
    Steiner S; Moertl D
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):975-84. PubMed ID: 23984925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation and antiplatelet therapy in acute coronary syndromes.
    Singh D; Gupta K; Vacek JL
    Cleve Clin J Med; 2014 Feb; 81(2):103-14. PubMed ID: 24493493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    Bhatt DL
    N Engl J Med; 2007 Nov; 357(20):2078-81. PubMed ID: 17982183
    [No Abstract]   [Full Text] [Related]  

  • 37. [New antithrombotic drugs].
    Mustonen P; Puurunen M
    Duodecim; 2012; 128(7):707-18. PubMed ID: 22612021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
    Cairns JA; Eikelboom J
    J Am Coll Cardiol; 2008 Dec; 52(24):1978-80. PubMed ID: 19055988
    [No Abstract]   [Full Text] [Related]  

  • 39. Prasugrel STEMI subgroup analysis.
    Shil AB; Strohm MP
    Lancet; 2009 May; 373(9678):1846; author reply 1846-8. PubMed ID: 19482212
    [No Abstract]   [Full Text] [Related]  

  • 40. Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
    Price MJ
    JAMA; 2012 Nov; 308(17):1806-8. PubMed ID: 23117783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.